| __timestamp | Lantheus Holdings, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 13673000 | 7459000 |
| Thursday, January 1, 2015 | 14358000 | 11831000 |
| Friday, January 1, 2016 | 12203000 | 25705000 |
| Sunday, January 1, 2017 | 18125000 | 46181000 |
| Monday, January 1, 2018 | 17071000 | 59497000 |
| Tuesday, January 1, 2019 | 20018000 | 65003000 |
| Wednesday, January 1, 2020 | 32788000 | 74506000 |
| Friday, January 1, 2021 | 44966000 | 126006000 |
| Saturday, January 1, 2022 | 311681000 | 126215000 |
| Sunday, January 1, 2023 | 77707000 | 120161000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, how companies allocate their research and development (R&D) funds can be a key indicator of their strategic priorities. Lantheus Holdings, Inc. and Protagonist Therapeutics, Inc. have shown distinct patterns in their R&D investments over the past decade. From 2014 to 2023, Lantheus Holdings increased its R&D spending by over 470%, peaking in 2022 with a significant surge. Meanwhile, Protagonist Therapeutics consistently ramped up its R&D budget, achieving a remarkable 1,600% increase by 2023. This trend underscores Protagonist's aggressive pursuit of innovation, while Lantheus's fluctuating investments suggest a more strategic, perhaps project-based approach. As these companies continue to evolve, their R&D strategies will likely play a pivotal role in shaping their future success.
Eli Lilly and Company vs Lantheus Holdings, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Sanofi and Lantheus Holdings, Inc.
Research and Development: Comparing Key Metrics for argenx SE and Protagonist Therapeutics, Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Sarepta Therapeutics, Inc. vs Lantheus Holdings, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and Protagonist Therapeutics, Inc.
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Blueprint Medicines Corporation or Lantheus Holdings, Inc.: Who Invests More in Innovation?
Research and Development Investment: Lantheus Holdings, Inc. vs Apellis Pharmaceuticals, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Research and Development Expenses Breakdown: Veracyte, Inc. vs Protagonist Therapeutics, Inc.
Research and Development Investment: Protagonist Therapeutics, Inc. vs Evotec SE